-
NMPA Launches “Drug Standard Management Measures” to Enhance Drug Quality and Safety
•
The National Medical Products Administration (NMPA) has released the “Drug Standard Management Measures,” a set of guidelines aimed at standardizing and strengthening drug standard management. These measures are designed to ensure rigorous drug standards related to safety, effectiveness, and controllable quality, with the ultimate goal of promoting high-quality development of…
-
China’s MofCOM Hosts Symposium with Multinational Corporations, Promises Development Opportunities
•
This week, China’s Ministry of Commerce (MofCOM) convened a symposium attended by representatives from a dozen non-China-based multinational corporations (MNCs). Minister of Commerce Wang Wentao engaged with the attendees, hearing 25 individual suggestions and discussions on current market conditions from companies such as Bayer AG (ETR: BAYN), Novo Nordisk (NYSE:…
-
Genprex Inc. Receives Chinese Patent Protection for Reqorsa Immunogene Therapy
•
Texas-based gene therapy company Genprex Inc., (NASDAQ: GNPX), has reported receiving a patent protection award in China for its lead pipeline candidate, Reqorsa (ONC-001/2) immunogene therapy. The China Intellectual Property Administration (CNIPA) has granted patent No: 201780076886.X, which covers the use of the therapy in combination with PD-1 antibodies, providing…
-
Moderna Inc. Plans USD 1 Billion Investment in Shanghai for mRNA Vaccine Production
•
US-based mRNA specialist Moderna Inc. (NASDAQ: MRNA) has revealed further details of its entry into the China market, with an agreement that vaccines manufactured locally will remain exclusively within the China market, as reported by Reuters based on an email response from a company spokesperson. This agreement is part of…
-
CSPC Pharmaceutical Group Receives Marketing Approval for Desvenlafaxine in China
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving marketing approval in China for its Category 3 product, desvenlafaxine, signifying that it has passed the generic quality and consistency evaluation (GQCE). Desvenlafaxine: A Third-Generation Anti-DepressantDesvenlafaxine is a third-generation anti-depressant that functions by inhibiting the reuptake mechanism of 5-hydroxytryptamine norepinephrine,…
-
AbbVie’s Rinvoq Receives NMPA Approval for Moderate to Severe Crohn’s Disease Treatment
•
US pharmaceutical firm AbbVie (NYSE: ABBV) has announced receiving market approval from the National Medical Products Administration (NMPA) for its Rinvoq (upadacitinib), a selective JAK inhibitor, to treat moderate to severe active Crohn’s disease in adult patients who have a poor or intolerant response or a contraindication to one or…
-
Luye Pharma’s Goserelin Acetate Microspheres Approved by NMPA for Prostate Cancer Treatment
•
Luye Pharma Group (HKG: 2186) has announced that it has received market approval from the National Medical Products Administration (NMPA) for its injectable goserelin acetate in microsphere form, a treatment for prostate cancer requiring androgen castration therapy. This innovative formulation is designed to provide a smoother drug release during the…
-
CDE Releases 72nd Batch of Generic Reference Preparations with New Specifications
•
The Center for Drug Evaluation (CDE) has released the 72nd batch of chemical generic reference preparations, which includes 19 new specifications. Among these, 2 are injectable formulations. Additionally, information for 19 previously published specifications has been updated, with updates also involving 2 injectable drugs. The CDE is seeking public feedback…
